قالب وردپرس درنا توس
Home / Business / What happened on the stock market today

What happened on the stock market today



<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Shares ended a week with always highs with a Another day of strong gains when investors began looking forward to income reports coming next week Dow Jones Industrial Average (DJINDICES: ^ DJI) and S & P 500 (SNPINDEX: ^ GSPC ) posted record rods, with industrial and consumer discretionary sectors leading the way. "data-response time =" 16 "> Shares ended a week's holiday with another day of strong gains as investors began looking forward to revenue reports coming next week. Dow Jones Industrial Average (DJINDICES: ^ DJI) and S & P 500 (SNPINDEX: ^ GSPC) posted end, with industrial and consumer discretionary sectors leading the way. ] Today's Stock Market

Index

Percentages

Point Change

Dow

0.90%

243.95

S & P 500

0.46%

13.86

Data Source : Yahoo! Finance.

<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "For some shares, Illumina (NASDAQ: ILMN) notified of a stroke of income, and Novartis (NYSE: NVS) and Amgen drug treatment for Alzheimer's disease. " (NASDAQ: ILMN) warned of an income deficit , and Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN) announced errors of a candidate treatment of Alzheimer's disease.

Rising Graph and Up Arrows in Different Shades of Blue

Illumina Warns of Weakness in Sales

<p class = "canvas competence textile Mb (1.0em) Mb (0) – sm Mt) – sm" type = "text" content = "Shares of Illumina threw 16.1% after the sequencing leader issued previous results & nbsp; for the second quarter that reported disappointing sales and lowered guidance for the entire year Illumina said it expects to report second-quarter revenue increased by 0.6% to $ 835 million, about $ 45 million less than analysts expected. The company led to a full-year revenue growth of 6%, less than half of 13% to 14% it had previously expected . "Data Reaction =" 34 "> Shares in Illumina ran 16.1% after Illesina said that it expects to report that revenue in the second quarter increased by 0.6% to $ 835 million, about $ 45 million less than analysts expected.

Illumina said that $ 30 million of income-related deficiency was related to population genomics measures, including a 6% revenue growth delay, and less than half of 13% to 14%. A big deal is expected to close later in the year. About $ 10 million was due to weakness in the direct consumer market, and $ 10 million was due to softness in the company's lower throughput systems.

<p class = "canvas -atom canvas text Mb (1.0em) Mb (0) – -sm Mt (0.8em) – sm" type = "text" content = "Illumina's stock price had occurred recently, and today's The move only returns it to where it was less than two months ago, but the full-year guidance means that half-year earnings will be about $ 200 million less than expected, and investors need to wait until the July 29 earnings report to understand why a decline Growth continues . "Data Reaction =" 36 "> Illumina's stock price had recently emerged, and today's move only returns to where it was less than two months ago. But the full-year guidance means that the half-income will be about $ 200 billion than expected, and investors need to wait for the income report on July 29 to understand why a slowdown in growth continues.

More Bad News for Alzheimer's Patients

The latest mistake in a drug to treat Alzheimer's disease was announced yesterday, when Novartis and Amgen said they discontinued work on CNP520, or umibecate, which was in clinical trials in late stage. The companies said that a central phase 2/3 study was halted following an evaluation identification d a deterioration of cognitive function and the potential benefit to the participants did not outweigh the risk. Novartis shares fell 2.4%, and Amgen dropped 1.7% on the news.

CNP520 was designed to bind to amyloid proteins that develop into plaque in Alzheimer's patients and was tested in people at high risk of developing age and genetics disease. Novartis and Amgen hoped that the drug would delay or prevent the onset of Alzheimer's.

<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm Eisenai recently thrown in the towel Biogen and Eisai on aducanumab, along with other busts Merck Eli Lilly and others. [amyloidhypothesis[194590004] & nbsp; may be dead at this point, and Biogen's BAN2401 candidate treatment may be next to fall. "data-response time =" 40 "> The error is just the latest among several attempts to treat Alzheimer's to attack amyloids. Biogen and Eisai recently threw the towel on aducanumab, joined with other busts of Merck Eli Lilly and others. The Amyloid hypothesis may be dead at this time, and Biogen's BAN2401 candidate treatment may be the next case.

<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt 0.89) – sm" type = "text" content = " More from The Motley Fool " data -reactid = "42"> More from The Motley Fool

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " Jim Crumly owns shares in Illumina. Motley Fool owns and recommends the BIIB and Illumina. Motley Fool recommends AMGN. Motley Fool has a disclosure policy . "data-response time =" 51 "> Jim Crumly ] owns shares in Illumina. Motley Fool owns and recommends the BIIB and Illumina. Motley Fool recommends AMGN. Motley Fool has a disclosure policy .


Source link